Source comparison
CJC-1295 no DAC & Ipamorelin Vial Size: Configuration Comparison
Selecting the optimal vial configuration depends on administration frequency, dose per injection, and protocol duration. The table below compares standard CJC-1295 no DAC & Ipamorelin vial size options against typical research protocols. 2mg / 2mg 1mL 2,000 ±3
This comparison does not assign a generated winner or score.
- Selecting the optimal vial configuration depends on administration frequency, dose per injection, and protocol duration. The table below compares standard CJC-1295 no DAC & Ipamorelin vial size options against typical research protocols.
- 2mg / 2mg
- 1mL
- 2,000
- ±3–5mcg (0.05mL draw)
- 10 days
- Excellent. Minimal degradation
- Short-cycle studies, dose-finding protocols
- 5mg / 5mg
- 2mL
- 2,500
- ±5–8mcg (0.08mL draw)
- 25 days
- Good. Within optimal window
- Standard research cycles, combination stacks
- 10mg / 10mg
- 5,000
- ±10–15mcg (0.04mL draw)
- 50 days
- Marginal. Late-stage potency loss
- High-frequency protocols only (daily or BID dosing)
- 5mg / 10mg (mismatched)
- 2mL each
- 2,500 / 5,000
- ±8–12mcg (mixed volumes)
- Variable
- Poor. Unequal depletion rates
- Not recommended. Forces premature discard
- The 5mg/5mg configuration strikes the balance between cost-efficiency and peptide integrity. Research protocols dosing 200mcg CJC-1295 no DAC and 250mcg Ipamorelin three times weekly consume one 5mg vial pair in approximately 28 days. Right at the edge of the stability cliff. Daily dosing protocols consume the same vials in 20–25 days, preserving >92% potency throughout.
- Mismatched vial sizes create operational waste. If you pair a 5mg CJC vial with a 10mg Ipamorelin vial, the CJC depletes first. Forcing you to either discard half-full Ipamorelin vials or introduce dosing asymmetry mid-protocol. Match vial sizes to consumption rates for both compounds unless your protocol explicitly calls for unequal dosing ratios.